CAREDX, INC. vs Quest Diagnostics Inc, two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CDNA and DGX diverge most: on debt / equity, CDNA reads 0.00 and DGX reads 0.72; on operating margin, CDNA reads 85.8% and DGX reads 15.1%. The rest of the comparable metrics sit closer together. What DGX's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | CDNA | DGX |
|---|---|---|
| Price | $50.16 | $234.94 |
| Market cap | $2.6B | $26.3B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Mature |
| Implied growth (priced in) | — | -0.7% |
| P/E | 24.2 | 24.9 |
| P/B | 6.10 | 3.37 |
| P/S | 5.66 | 2.28 |
| EV/EBITDA | 19.8 | 14.2 |
| Revenue growth | +34.3% | +9.9% |
| Operating margin | 85.8% | 15.1% |
| Net margin | 24.2% | 9.2% |
| Return on equity | 26.1% | 13.6% |
| Return on assets | 20.8% | 6.3% |
| Return on invested capital | 24.6% | 9.6% |
| FCF yield | 3.4% | 5.1% |
| Dividend yield | — | 0.8% |
| Debt / equity | 0.00 | 0.72 |
| Current ratio | 4.58 | 1.59 |
| Altman Z (solvency) | 6.99 | 7.70 |
| Piotroski F (quality) | 5 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.